- Home
- UPS vs SNY Comparison
UPS vs SNY Comparison
Compare UPS & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UPS | SNY |
|---|---|---|
| Founded | 1907 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.1B | 104.5B |
| IPO Year | 1999 | 2001 |
Fundamental Metrics
Financial Performance| Metric | UPS | SNY |
|---|---|---|
| Price | $102.01 | $45.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 5 |
| Target Price | ★ $110.22 | $58.00 |
| AVG Volume (30 Days) | ★ 4.3M | 3.0M |
| Earning Date | 04-28-2026 | 04-23-2026 |
| Dividend Yield | ★ 6.15% | 3.47% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.73 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.87 | $3.49 |
| Revenue Next Year | $4.13 | $6.10 |
| P/E Ratio | $59.37 | ★ $6.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $82.00 | $40.89 |
| 52 Week High | $122.41 | $52.68 |
Technical Indicators
Market Signals| Indicator | UPS | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 38.93 | 64.55 |
| Support Level | $94.74 | $45.71 |
| Resistance Level | $102.89 | $48.66 |
| Average True Range (ATR) | 2.05 | 0.54 |
| MACD | -0.29 | 0.26 |
| Stochastic Oscillator | 7.36 | 94.68 |
Price Performance
Historical ComparisonAbout UPS United Parcel Service Inc.
As the world's largest parcel delivery company, UPS manages a massive fleet of more than 500 planes and 100,000 vehicles, along with many hundreds of sorting facilities, to deliver an average of about 22 million packages per day to residences and businesses across the globe. UPS' domestic US package operations generate around 65% of total revenue, while international package makes up 20%. Air and ocean freight forwarding and contract logistics make up the remainder.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.